Table 1.
Baseline characteristics
| Characteristics | Number (%) | |
|---|---|---|
| Number of patients | 22 (100) | |
| Sex | Men/women | 12 (54.5)/10 (45.5) |
| Age, years | Median/range | 55/24‐77 |
| Performance status | 0/1 | 12 (54.5)/10 (45.5) |
| Histologic type | Adenoid cystic ca. | 15 (68.2) |
| Malignant melanoma | 2 (9.1) | |
| Squamous cell ca. | 2 (9.1) | |
| Mucoepithelial ca. | 1 (4.5) | |
| Rhabdomyosarcoma | 1 (4.5) | |
| Carcinoma | 1 (4.5) | |
| Temporal fossa involvement | No/Yes | 6 (27.3/16 (72.7) |
| Intracranial involvement | No/Yes | 4 (18.2)/18 (81.8) |
| Brain parenchyma involvement | No/Yes | 15 (68.2)/7 (31.8) |
| Gross tumor volume, cc | Median/range | 59.5/9–120 |
| Carbon‐ion radiotherapy | ||
| Fractionation | 16 fractions /4 weeks | 22 (100) |
| Total dose | 52.8 Gy (RBE) | 1 (4.5) |
| 57.6 Gy (RBE) | 10 (45.5) | |
| 64.0 Gy (RBE) | 11 (50.0) | |
| Beam delivery | Passive/spot scanning | 17 (77.3)/5 (22.7) |
Abbreviation: RBE, relative biological effectiveness.